Skip to Content

Velcade Approval History

FDA Approved: Yes (First approved May 13, 2003)
Brand name: Velcade
Generic name: bortezomib
Dosage form: for Injection
Company: Millennium Pharmaceuticals
Treatment for: Multiple Myeloma

Velcade is an antineoplastic agent indicated for the treatment of multiple myeloma and mantle cell lymphoma.

Development History and FDA Approval Process for Velcade

DateArticle
Jan 24, 2012Approval FDA Approves Subcutaneous Administration of Velcade In All Approved Indications
Jan  5, 2010Approval FDA Approves Addition of Sustained Overall Survival Benefit to Label for Velcade (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Jun 23, 2008Approval FDA Approves Velcade (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Oct 15, 2007Approval FDA Expands Velcade (Bortezomib) for Injection Label for Patients with Multiple Myeloma
May 13, 2003Approval FDA Approves Velcade (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide